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Abstract
Background: The P. falciparum chimeric protein 2.9 (PfCP-2.9) consisting of the sequences of MSP1-19 and AMA-1 (III) is a
malaria vaccine candidate that was found to induce inhibitory antibodies in rabbits and monkeys. This was a phase I
randomized, single-blind, placebo-controlled, dose-escalation study to evaluate the safety and immunogenicity of the PfCP-
2.9 formulated with a novel adjuvant Montanide ISA720. Fifty-two subjects were randomly assigned to 4 dose groups of 10
participants, each receiving the test vaccine of 20, 50, 100, or 200 mg respectively, and 1 placebo group of 12 participants
receiving the adjuvant only.
Methods and Findings: The vaccine formulation was shown to be safe and well-tolerated, and none of the participants
withdrew. The total incidence of local adverse events (AEs) was 75%, distributed among 58% of the placebo group and 80%
of those vaccinated. Among the vaccinated, 65% had events that were mild and 15% experienced moderate AEs. Almost all
systemic adverse reactions observed in this study were graded as mild and required no therapy. The participants receiving
the test vaccine developed detectable antibody responses which were boosted by the repeated vaccinations. Sixty percent
of the vaccinated participants had high ELISA titers (.1:10,000) of antigen-specific antibodies which could also recognize
native parasite proteins in an immunofluorescence assay (IFA).
Conclusion: This study is the first clinical trial for this candidate and builds on previous investigations supporting PfCP-2.9/
ISA720 as a promising blood-stage malaria vaccine. Results demonstrate safety, tolerability (particularly at the lower doses
tested) and immunogenicity of the formulation. Further clinical development is ongoing to explore optimizing the dose and
schedule of the formulation to decrease reactogenicity without compromising immunogenicity.
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Introduction
The emergence of drug-resistant parasites and insecticide-
resistant Anopheles mosquitoes have contributed to the persistence
of malaria in the world [1,2,3]. New methods to control the disease
are needed, and vaccination holds the promise of controlling and
perhaps eventually eradicating malaria.
The asexual blood stage is responsible for malaria disease.
Naturally acquired immunity develops against disease in malaria-
endemic regions, where parasite density is observed to decrease
with age and the clinical manifestations of malaria are generally
much milder in adults than in children under 5 years of age [4,5].
Moreover, immunoglobulin fractions from adults in these high-
transmission areas have been found to passively reduce parasit-
emia in infected children [6,7].Thus an effective vaccine targeting
this stage and inducing immune responses similar to that obtained
by natural infection could reduce morbidity and mortality of the
disease.
Several antigens thought to be targets of protective blood-stage
immune responses have been identified [8,9,10]. Among them, the
,200 kDa Merozoite Surface Protein 1 (MSP1) and the Apical
Membrane Antigen 1 (AMA-1) of Plasmodium falciparum are two
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the merozoite surface, they are proposed to play a role in the
process of parasitic invasion [11,12]. A portion of MSP1
recognized by protective antibodies was mapped to the 19 kDa
carboxy-terminal region (MSP1-19) which contains two epidermal
growth factor (EGF)-like domains [13]. Immunization with MSP1-
19 of P. falciparum in monkeys and P. yoelii in mice induced
protection against homologous parasite challenge [14,15]. Data
from these animal studies were supported by in vitro studies
showing that MSP1-19 specific antibodies inhibited merozoite
invasion [16].
AMA-1 is an integral membrane protein of 83 kDa. Studies in
rodent and monkey models demonstrated that immunization with
native or recombinant AMA-1 can provide protection against
homologous parasite challenge [17]. A three-domain sub-structure
of the AMA1 ectodomain was recently suggested [18]. The most
C-terminal of the disulphide-bonded domains in AMA-1 (domain
III) containing a ‘‘cysteine knot-like’’ structure may be carried on
the surface of the invading merozoite along with MSP1-19. Studies
with P. chabaudi in a mouse model have shown that antibody-
mediated protection can be induced by immunizing with the
AMA1 ectodomain [19]. The structure of AMA-1 (III) was
recently demonstrated to be the target of inhibitory antibodies
isolated from humans in malaria-endemic regions [20]. A recent
study showed that AMA-1(III) bound to the erythrocyte
membrane protein, Kx, and that the subsequent rate of invasion
of Kx null erythrocytes was reduced, suggesting that AMA-1 (III)
plays an important role in merozoite invasion of human
erythrocytes [21].
Both MSP1-19 and AMA-1 (III) can be a target of inhibitory
antibodies, but the small size of the antigens may limit the ability
of each alone to adequately induce the high titer of antibodies that
may be required to be effective in vivo. Polyvalent subunit malaria
vaccines containing multiple protective domains or epitopes from
different antigens may be necessary for enhanced immunogenicity
and protective efficacy and may be needed to address the issue of
parasite variation. Chimeric protein vaccine constructs may be an
approach towards this and therefore, we have constructed a P.
falciparum chimeric protein 2.9 (PfCP-2.9) by combining MSP1-
19 and AMA-1 (III) sequences [22]. The purified PfCP-2.9
protein, produced by Pichia pastoris in secreted form with a yield
of 2,600 mg/L, was highly immunogenic in rabbits as well as in
rhesus monkeys (Macaca mulatta). It induced both anti-MSP1-19
and anti-AMA-1 (III) antibodies at 11- and 18-fold higher titers,
respectively, compared to individual components. Anti-PfCP-2.9
sera from rabbits and rhesus monkeys at a 6 to 7-fold dilution
nearly completely inhibited in vitro growth of the P. falciparum
FCC1/HN and 3D7 strains [22]. The inhibition was dependent
on the presence of antibodies to the chimeric protein and their
disulfide bond-dependent conformations. Moreover, the activity
was mediated by a combination of growth-inhibitory antibodies
generated by the individual MSP1-19 and AMA-1 (III) compo-
nents of PfCP-2.9.
In this study, we report the first human phase I trial of
recombinant PfCP-2.9 formulated with the novel adjuvant
Montanide ISA720 [23,24].
Methods
Study Setting
The Phase I trial was a randomized, single blinded, placebo-
controlled, dose-escalation study conducted at theChinese Nation-
al Medicament Clinical Study Base, Changhai Hospital in
Shanghai, China. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Participants
Seventy-two healthy malaria-naı ¨ve adults were screened after
have given written informed consent. Exclusion criteria included a
history of malaria or positive markers for antibodies to malaria
parasite by IFA; history of traveling to or residing in a malaria
endemic region within the last two years; history of allergic
reactions or convulsions following vaccination; acute illness within
four weeks prior to the trial; involvement in any other drug or
vaccine trial within four weeks prior to enrollment; presence of any
chronic disease or HBV (HBsAg) and HCV infection; pregnancy;
abnormal hematology and clinical chemistry and elevated levels of
anti-nuclear antibodies(.160). 62 volunteers were found eligible
and enrolled. They were randomly allocated as 52 participants in
5 groups and 10 standbys. 4 groups (10 participants each group)
received the vaccine formulation of either 20 mg, 50 mg, 100 mgo r
200 mg while the fifth (12 participants) received placebo.
Intervention
The PfCP-2.9 chimeric protein was constructed and produced
in P. pichia as described before[22]. Briefly, the redesigned
synthetic gene encoding the chimeric protein was expressed in
the yeast system in a secreted form at an extremely high yield of
2.6 g/L in a 15-liter fermentation run. The recombinant protein
resembled closely its native protein as all six conformational
monoclonal antibodies interacted with the protein. To prepare for
this study, three batches of the protein (lots No. 20010501,03)
were produced at the 30-L scale at the Pilot Bioproduction Facility
of Shanghai Wanxing Bio-pharmaceutical Co. Ltd. The condi-
tions for the fermentation of the construct were optimized to
achieve high level expression. The protein was purified through
hydrophobic interaction, ion-exchange and gel filtration chroma-
tography. The purified protein was a single band and more than
99% pure as measured by SDS-PAGE and HPLC. It contained
,2.5 endotoxin units per dose and ,0.1% host protein. In
addition, N-terminal sequences of the purified protein were
determined by Edman degradation from the first residue to
position 15 which found the determined sequence to be identical
to the designed sequence. The protein reacted with the
conformational monoclonal antibody mAb5.2 recognizing
MSP1-19 (see Data S1 of this paper).
The purified protein was formulated with the Montanide
ISA720 adjuvant by mixing 70% volume of the adjuvant with
30% volume of the antigen solution using a Homogeneizer at
4000 rpm for 4 min at room temperature. The parameters for
homogenization of the vaccine emulsion were determined in prior
experiments to achieve an acceptable size of approximately 1 mm
diameter(the manufacturer of the ISA 720 adjuvant kindly carried
out this detection using laser diffraction-based particle size
analyzer) although the vaccine emulsion lots used in the clinical
trial were not analyzed for droplet size distribution. The quality of
the emulsion was controlled by several parameters including
droplet test and conductivity. The formulated vaccine was
characterized as follows: conductivity (25uC) was about 0.1 ms,
viscosity (25uC) about 15 mPas and microscopic appearance was
homogeneous dispersion of small and regular droplets (about 1 mm
in diameter). After passing sterility tests, the vaccine was packaged
into autoclaved 2 mL bottle with 1 mL volume of emulsion.
Similarly, the comparator emulsion used for placebo control was
prepared by mixing 70% volume of the adjuvant with 30%
volume of the PBS solution. To assess physical and biochemical
stability, SDS-PAGE gel with Commas-blue and silver staining,
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developed by us were utilized on the vaccine emulsion lots used
in the pre-clinical study (manuscript in preparation). In addition
potency was evaluated with immunogenicity studies in mice
(ED50). Vaccine emulsions were stored at 4uC and tested at regular
intervals. The results showed that the vaccine was stable for at least
one year and a half, although the aggregation of the protein was
observed during the storage at 4uC. There were no significant
changes of the potency and GIA efficacy of the stored emulsion
compared with the fresh emulsion. Moreover, the nature of the
protein in the emulsion was detected by the sandwich ELISA
method which showed that the conformation of the protein in the
emulsion after 18 months was not changed. Based on the stability
and potency of the pre-clinical vaccine formulation lots, we
developed a protocol to produce four lots of 400 mg, 200 mg,
100 mg and 40 mg of the vaccine formulation for use in the clinical
study. Physical and biochemical stability and potency of the
clinical vaccine lots were evaluated for six months. The results
showed that all the clinical lots of the formulation were stable
during the period of six months. No degraded band of this protein
was detected by SDS-PAGE with Commas-blue staining and the
ED50 of the vaccine emulsion stored for 0, 3 and 6 months at 4uC
were 0.037, 0.032 and 0.033 mg, respectively, which showed no
significant changes between the fresh formulation (0 month) and
post-storage formulation for 3 and 6 months ( see Data S1 of this
paper).
On day 0, three participants in the 20 mg group and one in the
placebo group were injected intramuscularly in the left lateral
deltoid with 0.5 mL of vaccine or placebo formulation, respec-
tively. Following a review of safety data by the study Data Safety
Monitoring Board (DSMB), after a two week interval, the
remaining participants from the 20 mg group and placebo were
injected. A similar review and 2 week interval preceded before
injecting the next group at higher doses.. The participants in rest
of the groups were immunized in a similarly staged manner. The
vaccinations were repeated on Day 60 in the right lateral deltoid
and on Day180 in the left one.
Clinical Oversight, Ethical and Regulatory Approval
The sponsor, World Health Organization, convened a study
team which reviewed the trial protocol and monitored the study
conduct on site regularly. Safety data from the study was evaluated
by the Data Safety Monitoring Board (DSMB). Ethical approval
was obtained by Independent Ethics Committee (IEC) of
Shanghai Changhai Hospital and the WHO Ethical Review
Committee (ERC) (then known as Secretariat Committee for
Research Involving Human Subjects).
The vaccine candidate was approved for clinical trial by the
State Food and Drug Administration in China (SFDA).
Study design and procedures
Objectives. The objectives of the study were to evaluate the
safety, reactogenicity and immunogenicity of the PfCP-2.9
recombinant vaccine adjuvanted with Montanide ISA 720
(SEPPIC, France) in healthy adults.
Outcomes. Safety and Reactogenicity: After each injection
participants were observed for 24 h to identify and treat
immediate reactions and symptoms. Diary cards were distributed
and participants were instructed to record adverse events daily for
14 days post injection. After each injection, participants were seen
at 24 hours, 48 hours, day 7 and day 14. At each visit, the
injection site was examined and the subjects were asked about
adverse events. Additionally, participants were interviewed for any
abnormal signs or symptoms on Day 30, 60, 61, 62, 74, 90, 180,
181, 182, 194 and 240 after each vaccination. Blood samples (10–
20 mL) for complete blood count (CBC) and differential,
measurement of blood creatinine level, AST, ALT, urine
sedimentation, were drawn at screening and on Day 0, 30, 60,
90, 180 and 240.
Clinical adverse events (AEs) were classified into local and
systemic events. Solicited local adverse events included tenderness,
local pain, swelling, induration, nodule, ulceration, itching and
erythema. Systemic adverse events included fever, rash, headache,
nausea, hypertension, hypotension, and abdominal pain. The
intensity of the AEs were graded mild (grade 1; well-tolerated),
moderate (grade 2; interfering with daily activities) or severe (grade
3; preventing normal daily activities). Causality relationship to the
vaccine was categorized as definite, probable, possible, unlikely or
not related.
Immunogenicity
All immunological analyses was performed according to
standard operating procedure (SOP) documents available on-site.
All the time-point samples (collected on Day 0, 30, 60, 90, 180,
194 and 240) from participants were analyzed by IFA for
determination of antibodies to cultured parasite of P. falciparum
FCC1/HN isolate, ELISA for IgG to PfCP-2.9 recombinant
protein and lymphocyte proliferation assay for T cell immune
response to the antigen. Sera post three immunizations ( on day
194) were tested for their ability to inhibit growth of the parasite in
an in vitro growth inhibition assay (GIA).
Responders to the vaccine was defined at two levels: responders
were those with ELISA titers specific for PfCP-2.9 protein greater
than 1:500 and high responders were those with titres greater than
1:10,000. Lymphocyte responder was defined as a participant
whose lymphocyte stimulation indices are greater than 3.
ELISA
ELISA was performed in triplicate on diluted serum samples in
96-well flat-bottomed micro-titer plates. Micro-titer plates
(Thermo Lab systems) were coated for 1 h at 37uC with 100 mL
of recombinant protein at the concentration of 1.0 mg/mL diluted
in carbonate buffer (0.159% Na2CO3, 0.293% NaHCO3,
pH 9.6). The antigen solution was removed and the plates were
blocked with PBS containing 3% skim milk at 37uC for 1 h.
100 mL of serum samples at various dilutions were added to the
plates, and incubated at 37uC for 1 h. 100 mL of peroxidase-
conjugated horse anti-human IgG were added to the plate at
1:1000 dilution in PBS containing 3% skim milk for a further 1 h
incubation at 37uC. For every step, plates were washed three times
with PBST (PBS containing 0.05% Tween 20) and one time with
PBS using a plate washer. Bound secondary antibodies were
detected by adding 100 mL of TMB (3,39, 5,59-Tetramethyl
Benzidine) substrate solution at room temperature for 10 min, and
the reaction was stopped by adding 50 mLo f2MH 2SO4. The
plates were read at an absorbance of 450 nm (ELx800 ELISA
reader, BIO-TEC Instrument INC). Cutoff values were deter-
mined as the mean plus three standard deviations for the pre-
immune sera.
IFA
IFA was performed as previously described [22]. Cultured
parasites of Pf FCC1/HN isolate were used as antigens. IFA slides
were prepared using culture material with a 5%–10% parasitemia.
The slides were blocked with 3% nonfat powdered milk in PBS
before adding serum samples at various dilutions and incubated for
1 h at room temperature. After being extensively washed with PBS,
the slides were incubated with fluorescein isothiocyanate-labeled
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for 1 h at room temperature. The bound secondary antibodies
were examined by fluorescence microscope. End-point titers
were determined as the last dilution above the background that
fluorescent parasites were observed in pre-immune sera.
Proliferative T cell assay
T-cell responses to the antigen were measured by a lymphocyte
proliferation assay. Mononuclear cells from the peripheral blood
obtained from the participants were isolated by Ficoll-Hypaque
density gradient centrifugation. The collected mononuclear cell
were diluted to a concentration of 16106/mL in complete RPMI
1640 containing 10% FCS, 10 mmol/L Hepes, 1 mmol/L sodium
pyruvate, 2 mmol/L glutamine, 0.075%NaHCO3, 100 mg/mL
streptomycin, and 100u/mL penicillin. 100 mL of the cell
suspension and 100 mL medium with or without the vaccine
antigen were dispensed into 96-well plate in triplicate. After
culture at 37u, 5%CO2 for 60 h, the culture were pulsed with
1 mci of [3H]TdR for 12 h before harvesting the cells using a semi-
automated sample harvester. Its incorporation was determined by
b-scintillation counter. Results were expressed as fold increases in
stimulation index (SI), calculated as post-vaccination SI divided by
pre-immune SI.
Growth Inhibition Assay
The immune sera post three immunizations ( on day 194) were
tested for their ability to inhibit growth of the parasite in vitro.
Plasmodium falciparum FCC1/HN parasite line was used for the
assay. FCC1/HN line was isolated from Hainan Island, China and
its continuous cultivation in vitro was established in 1979 [22]. The
parasite culture with a majority of rings was synchronized by
treatment with 5% sorbital. The inhibition assay was performed
with the starting culture containing 2% hematocrit and approx-
imately 0.3% parasitaemia using the synchronized parasite with
mostly late-trophozoites and schizonts. 170 mL of the culture
suspension and 30 mL of the test serum were added in triplicate
wells to 96-well flat-bottomed plates and incubated at 37uC for
72 h. Thin blood smears were prepared to determine parasitae-
mia. The inhibition rate was determined according to the
following: %inhibition=[(1-(Pt-Ps)/(Pc-Ps) ]6100%. Pc: parasit-
emia of pre-immune sera; Pt: parasitemia of immune sera; Ps:
parasitemia of starting culture.
Sample size. The sample size for this study was based on the
primary objective of evaluating safety of each dose level. The study
was not powered to detect statistically significant differences in the
frequency of adverse events or immunogenicity between different
study arms. The number of subjects in each study arm (10) is a
generally acceptable sample size in a Phase I study for detecting
large differences in the frequency of adverse events with
reasonable accuracy.
Randomization. Two numbers were generated for each
volunteer in the study, a screening number and a randomization number.
The screening number was given to the participants at the first
screening visit (composed of 3 digits starting with 001 and given in
a sequential fashion).
Randomization numbers composed of 3 digits starting with 801
and specifying a treatment code were generated by the data
management team and were randomly assigned to the eligible
participants meeting all inclusion and none of the exclusion
criteria, prior to vaccination on Day 0. The initials, screening
number and the randomization number will be written by the
vaccine injector on the ‘‘Vaccine Information and Administration
Form’’ accompanying each treatment vial.
Blinding
The administration of the vaccine was single-blinded in that
study participants were blinded to the vaccine assignment. Only
the study pharmacists had access to the randomization codes that
revealed the dose group allocation. However the investigators and
outcome assessors were not blinded to the dose group allocation.
Statistical methods
Descriptive statistics were used to analyse the study data. Local
and systemic events were summarized as frequency tables of
numbers of adverse events by vaccination sequence, study arm and
intensity of reported event. Immunogenicity data was summarized
by vaccine group as geometric mean titres (GMTs) and the
associated 95% confidence interval if required. Mixed models
were used to analyse immunogenicity parameters and laboratory
tests among groups over time. If the mixed models analysis showed
a significant difference between groups, Fisher’s LSD was used to
analyse the difference between any two groups at each time point.
All statistical analyses tests were performed at an individual
significance level of 5% and were two-sided and regarded as
exploratory. SAS 8.2 was used for the statistical analyses.
Results
Participant flow, recruitment and baseline data
Prior to starting the study, workers in factories, students in
universities and residents in Shanghai were invited to attend an
information meeting to describe the clinical trial. Within a month
of scheduled enrollment, all individuals who agreed to participate
from the previously held information meeting were invited to
consent for the study. Inclusion and exclusion criteria were
checked and the participants were provided with a screening
number (3 digits in a sequential fashion). The study physicians took
the clinical history and conducted a physical examination for
screening purposes.
Seventy-two participants were screened according to the inclusion
and exclusion criteria, and 62 participants were enrolled (Fig 1). Fifty-
two participants were enrolled as participants and randomly allocated
to 4 vaccine groups (10 per group receiving 20 mg, 50 mg, 100 mgo r
200 mg doses) and one placebo group of 12. The remaining 10
participants were enrolled as standbys in case any withdrawals
occurred before the first vaccination. Noparticipants were withdrawn
or removed during the study from August 11, 2003 through
November 18, 2004, and all received the three scheduled
vaccinations. The numbers analyzed include all 52 participants.
The 52 participants, 32 males and 20 females, were all Chinese with
ages ranging from 18 to 45 and a mean age of 24.5.
Outcomes and estimation
Safety and reactogenicity. Local adverse events observed
during the trial included tenderness, pain, swelling, induration,
erythema or redness and itching. All local AEs related to the
vaccination resolved within 1 to 2 weeks without treatment.
Neither vaccine nor placebo recipients experienced any grade 3 or
severe reactions.
The most common adverse event reported was tenderness (58%).
This was followed by swelling (18%), induration (9%) and painat the
injection site (10%). 93% of these events were graded as grade 1 or
mild in intensity. 75% of the vaccinees experienced tenderness ,
followed by swelling (42%), local pain (25%), induration(23%),
itching (8%), and redness at the injection site (5%). 58% of
participants in the placebo control group compared with 80% of
total participants in the vaccine groups experienced at least one local
adverse event (Table 1). All the events in the placebo group were
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that were graded mild and 15% (6 subjects) experienced moderate
adverse events. There was a trend towards more adverse reactions
and slightly more moderate adverse reactions with increasing
vaccine dose and number of immunizations (Table 2). 8 events of
grade 2 or moderate intensity that occurred in the six participants
included induration (4 events) and swelling (2 events). 5 were from
the highest dose cohort (200) and one from the lowest dose
cohort(20). The moderate AE (swelling) in the volunteer receiving 20
dose followed the second immunization.
17 vaccinees developed swelling, 30% of the 20 mg, 50 mg , and
100 mg respectively and 80% of the vaccinees in the 200 mg group
(Table 3). All except two were graded mild.
Discrepancies in defining a nodule versus induration due to
differences in the terminology used in Mandarin versus English
resulted in some difficulties in interpretation of the diagnosis of
suspectednodules.Forexample,theterm‘knot’isaliteraltranslation
of the Mandarin term used to describe some of the observations
suspected as nodules, but it was not possible to fully define and
conclude if it was distinguished from induration or swelling in all
cases. As a result, all suspected cases of nodules were classified under
induration as shown in Table 4. A total of 9 participants developed
mild to moderate induration within 2 to 4 weeks post-vaccination
(delayed reaction) in the 50 mg (20%) , 100 mg (10%) and 200 mg
(60%) vaccine groups, whereas induration was not observed in
participants receiving 20 mg of the vaccine antigen or the placebo
(Table 4). Moreover, only participants (3) receiving the highest dose
of the vaccine (200 mg) developed induration graded as moderate.
The size of the induration ranged from less than 2 cm to up to 4 cm
in diameter. These data suggest that development of induration and
its severity is likely related to the vaccine formulation and is dose-
dependent. More participants receiving the highest vaccine dose
experienced swelling and induration than those in the lower dose
cohorts. In addition, no AEs apart from tenderness were observed in
the placebo group. Therefore, these adverse events were likely
related to the vaccine.
Systemic adverse reactions observed in this study include fever,
rash, headache, hypotension and hypertension, abdominal pain,
Figure 1. Study enrollment flow diagram.
doi:10.1371/journal.pone.0001952.g001
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hypertension (20%) were the most frequently reported (Table 1),
occurring at a similar rate in the placebo control group [(10/
12)100=83%] as well as in the vaccine groups [(31/
40)100=78%]. All the events were graded as mild, except for in
one participant, in which it was grade as moderate. All were
asymptomatic and resolved spontaneously. Moreover, the events
were similar for participants receiving the vaccine or placebo, and
there was no trend towards increased reactions with increasing
doses of the vaccine. It is worth noting here that in the protocol,
hypertension after vaccination was defined as diastolic pressures
transiently increasing .10 mmHg compared to the blood pressure
measured before injection, while hypotension was defined as a
systolic pressure decrease of .10 mm Hg. This is likely more
rigorous than that of standard clinical practice and likely
contributed to the high rates of hypotension and hypertension.
The other systemic adverse events, including fever in 2, rash in 1,
headache in 1, diarrhea in 2 and common cold in 4 participants
were judged to be not related to vaccination.
Results from the mixed model analysis of laboratory tests
indicated that no significant differences (P.0.05, Fisher tests of
fixed effects) were observed between vaccine groups and placebo
group as well as between different time-point samples. Four
participants were reported to have a mild decrease in white
blood cell account on day 90 and one volunteer to have a mild
elevation in ALT and AST on Day 30, but the values returned
to normal without therapy and judged to be unrelated to
vaccination.
During the trial, no serious adverse events or unexplained
illnesses occurred in the participants. One volunteer in the placebo
group suffered from acute appendicitis after the second injection
and was operated on. The volunteer received the third injection
following his recovery. The event was judged not to be related to
the vaccination.
Table 2. Number (percentage) of subjects experiencing local solicited adverse events for each study arm receiving vaccine, by
intensity grade for each immunization.
Immunization
schedule First immunization (N=10) Second immunization (N=10) Third immunization (N=10)
Intensity Any G1 G2 G3 Any G1 G2 G3 Any G1 G2 G3
20 mg
Tenderness 1(10) 1(10) 0 0 0 0 0 0 4(40) 4(40) 0 0
Pain 0 0 0 0 6(60) 5(50) 1(10) 0 1(10) 1(10) 0 0
Swelling 0 0 0 0 2(20) 1(10) 1(10) 0 2(20) 2(20) 0 0
Induration 0 0 0 0 0 0 0 0 0 0 0 0
Erythema 0 0 0 0 0 0 0 0 0 0 0 0
Itching 0 0 0 0 0 0 0 0 1(10) 1(10) 0 0
50 mg
Tenderness 1(10) 1(10) 0 0 5(50) 4(40) 1(10) 0 4(40) 4(40) 0 0
P a i n 0 00 0 0000 0 00 0
Swelling 1(10) 1(10) 0 0 0 0 0 0 2(20) 2(20) 0 0
Induration 2(20) 2(20) 0 0 0 0 0 0 0 0 0 0
Erythema 0 0 0 0 0 0 0 0 0 0 0 0
Itching 0 0 0 0 0 0 0 0 0 0 0 0
100 mg
Tenderness 4(40) 4(40) 0 0 6(60) 6(60) 0 0 5(50) 5(50) 0 0
Pain 2(20) 2(20) 0 0 0 0 0 0 0 0 0 0
Swelling 0 0 0 0 0 0 0 0 3 3 0 0
Induration 1(10) 1(10) 0 0 1(10) 1(10) 0 0 0 0 0 0
Erythema 0 0 0 0 0 0 0 0 0 0 0 0
Itching 1(10) 1(10) 0 0 0 0 0 0 0 0 0 0
200 mg
Tenderness 7(70) 7(70) 0 0 6(60) 6(60) 0 0 8(80) 8(80) 0 0
Pain 1(10) 1(10) 0 0 1(10) 1(10) 0 0 0 0 0 0
Swelling 1(10) 1(10) 0 0 2(20) 2(20) 0 0 8(80) 7(70) 1(10) 0
Induration 4(40) 1(10) 3 0 1(10) 1(10) 1(10) 0 2(20) 1(10) 1(10) 0
Erythema 0 0 0 0 0 0 0 0 2(20) 2(20) 0 0
Itching 0 0 0 0 0 0 0 0 1(10) 1(10) 0 0
Note: N represents the number of participants randomized into each study arm, receiving at least one immunization. Denominators are participants receiving at least
one immunization for each study arm. Each participant is counted at the most once for each event type per vaccination and the greatest reported intensity level is
recorded. For the control group, the only observed event reported was mild tenderness (grade 1); 3 occurred following first immunization; 4 after the second
immunization and 5 following the third immunization.
doi:10.1371/journal.pone.0001952.t002
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No per dose group Gender Immunization Intensity Duration (days) Resolution
20 mg
1 Male Second Grade 1 7 spontaneous
Third Grade 1 5
2 Male Second Grade 2 3 spontaneous
3 Female Third Grade 1 2 spontaneous
50 mg
1 Male First Grade 1 2 spontaneous
2 Female Third Grade 1 4 spontaneous
3 Male Third Grade 1 2 spontaneous
100 mg
1 Female Third Grade 1 6 spontaneous
2 Female Third Grade 1 2 spontaneous
3 Female Third Grade 1 6 spontaneous
200 mg
1 Female First Grade 1 4 spontaneous
Second Grade 1 10
Third Grade 1 7
2 Female Second Grade 1 5 spontaneous
Third Grade 1 5
3 Male Third Grade 1 3 spontaneous
4 Male Third Grade 2 3 spontaneous
5 Male Third Grade 1 3 spontaneous
6 Female Third Grade 1 4 spontaneous
7 Female Third Grade 1 3 spontaneous
8 Male Third Grade 1 3 spontaneous
doi:10.1371/journal.pone.0001952.t003
Table 4. Characteristics and evolution of induration* following immunization occurring in the study.
No per dose
group Gender Immunization Intensity Nodule-like features
Duration
(days) Resolution
50 mg
1 Female First Grade 1 ‘knot’ at injection site 18 days post-immunization 9 spontaneous
2 Female First Grade 1 5 spontaneous
100 mg
1 Female Second Grade 1 ‘knot’ at injection site 13 days post-immunization 13 spontaneous
200 mg
1 Male First Grade 2 5 spontaneous
2 Female First Grade 1 ‘knot’ at injection site 14 days post-immunization 6 spontaneous
3 Female First Grade 2 4 spontaneous
4 Female First Grade 2 ‘knot’ at injection site 15 days post-immunization 4 spontaneous
5 Male Second Grade 1 ‘knot’ at injection site 15 days post-immunization 6 spontaneous
Third Grade 2 8 spontaneous
6 Male Third Grade 1 ‘knot’ at injection site 15 days post-immunization 7 spontaneous
*Note: Due to discrepancies in the defining and diagnosing nodules versus induration, all suspected nodules were classified as induration. The word ‘knot’ is a literal
translation of the mandarin word used to describe the AE.
There was no induration reported in the control or 20 mg dose groups.
doi:10.1371/journal.pone.0001952.t004
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ELISA titers: Antibodies specific to the PfCP-2.9 vaccine antigen
were measured by ELISA. A specific antibody response (titer
.1:200) was detected in all the participants receiving the vaccine
injection, whereas no specific antibody (titer ,1:200) was detected
in the placebo group. Depending on the post-immunization serum
antibody levels to PfCP-2.9, participants were labeled either
‘‘antibody responder’’ (titer .1:500) or ‘‘high antibody responder’’
(titer .1:10,000). According to this criteria, almost all participants
receiving the vaccine developed positive antibody responses to
PfCP-2.9 after the first immunization. Only 2 participants in the
50 mg group and 1 in the 200 mg group had titers below 1:500
(negative response) (Table 5, 6 and 7). After the second
vaccination, the antigen-specific antibody levels in all groups
significantly increased. However, these levels declined 4 months
later and 4 participants became negative (titer ,1:500). After the
third vaccination, antibody levels in all participants were boosted
and by day 240, the last study day, all participants had positive
antibody responses. The geometric mean ELISA titers were
15,193 in the 20 mg, 9,666 in the 50 mg, 9, 642 in the 100 mg and
10,530 in 200 mg vaccine dose groups (Table 5, 6 and 7).
The frequencies of high responders were as follows: 90% (9/10)
in the 20 mg group after the second immunization but decreased to
60% (5/10) after the third immunization; in the 50 mg group, 60%
after the second and 50% after the third vaccinations; in the
100 mg group, 30% after the second but increased to 60% after the
third vaccination; and 60% after the second and 70% after the
third vaccinations in the 200 mg group. No relationship was found
between antigen doses and frequencies of the high antibody
responders after the second and third vaccinations. The third
vaccination did not increase frequencies of high responders in the
20 mg and 50 mg groups, but it did so in the remaining two vaccine
groups.
A mixed model analysis of ELISA titers indicated that the
overall group effect was significant (Table 8; P,0.001). In
comparing antibody levels in participants receiving different doses
of the antigen, there were no significant dose-response relation-
ships among the 20 mg, 50 mg, 100 mg and 200 mg groups on day
30 (after the first vaccination), day 90 (after the second
Table 5. ELISA antibody titer in time-point serum samples
from participants in 20 and 50 mg groups.
Dose (mg)
No.
participants ELISA titres
Day30 Day 90 Day194 Day240
20 1 4,758 22,450 45,897 38,519
2 3,858 12,732 7,556 25,325
3 2,188 2,188 50,310 13,544
4 1,410 8,546 5,434 5,722
5 966 27,684 8,488 7,906
6 1,811 12,996 7,396 6,832
7 1,029 23,877 15,641 15,805
8 3,939 20,636 16,097 18,754
9 4,189 9,297 14,388 11,225
10 10,539 42,100 28,524 48,254
Geomean 2,660 14,352 15,097 15194
50 1 1,178 10,943 9,356 8,509
2 973 11,732 11,071 9,018
3 478 2,346 2,192 1,375
4 4,265 22,826 69,372 24,802
5 4,024 9,915 9,428 3,160
6 5,266 15,835 24,802 31,462
7 2,192 32,025 11,462 17,689
8 8,186 11,178 53,064 28,515
9 579 4,433 6,759 6,136
10 8,676 9,018 7,026 8,845
Geomean 2,317 10,444 12,667 9,666
Note: A: ELISA antibody titer to the PfCP-2.9 in pre-immune serum samples(Day
0) is ,1:100
B: ELISA antibody titer to the PfCP-2.9 in sera from participants receiving the
placebo injection is ,1:100
C. The first vaccination was performed on day 0 and boosted vaccination were
on days of 60 and 180
D. ND: not done
doi:10.1371/journal.pone.0001952.t005
Table 6. ELISA antibody titer in time-point serum samples
from participants in 100 and 200 mg groups.
Dose (mg)
No.
participants ELISA titres
Day30 Day 90 Day194 Day240
100 1 902 7,725 6,759 5,690
2 2,419 11,071 21,373 18,920
3 5,790 20,964 41,423 108,568
4 3,653 3,798 12,849 11,049
5 6,502 3,259 11,157 10,733
6 3,798 2,097 20,246 5,369
7 2,808 18,167 26,907 11,869
8 1,272 2,017 2,171 2,171
9 4,025 4,348 34,269 7,725
10 1,455 4,025 4,183 4,689
Geomean 2,740 5,591 13,070 9,642
200 1 318 2,012 2,269 1,833
2 3,850 111,274 71,096 74,079
3 12,864 37,370 74,079 37,140
4 1,216 10,539 23,391 25,447
5 667 3,840 3,619 2,143
6 1,891 11,003 13,294 11,004
7 1,295 9,908 12,473 7,074
8 5,061 11,465 28,259 28,846
9 345 1,023 1,149 1,764
10 2,698 15,701 18,205 ND
Geomean 1648 9621 12579 12579
Note: A: ELISA antibody titer to the PfCP-2.9 in pre-immune serum samples(Day
0) is ,1:100
B: ELISA antibody titer to the PfCP-2.9 in sera from participants receiving the
placebo injection is ,1:100
C. The first vaccination was performed on day 0 and boosted vaccination were
on days of 60 and 180
D. ND: not done
doi:10.1371/journal.pone.0001952.t006
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study day (day 240) (P.0.05, ANOVA/LSD). One exception was
in the comparison between the 20 mg and 100 mg groups on day
90 in which the geometric mean titer of 14,352 in the 20 mg group
was significant higher than that of 5,591 in the 100 mg group.
IFA titers: To determine whether the antigen-specific antibodies
from participants recognized native parasite proteins, we used an
in vitro cultured FCC1/HN strain of P. falciparum as antigen to
detect interactions of the serum samples from various time-points
(Day 0, 30, 60, 90, 180,194 and 240) with the parasite in an
immunofluorescence assay (IFA). As shown in Figure 2, 95% after
the second or 92.5% after the third vaccination of participants
receiving the vaccine formulation developed a detectable antibody
response to the parasite, and the antibody levels were significantly
increased after each boost vaccination (Fig. 3). In contrast, both
pre-immune sera and sera from participants receiving the placebo
had no reactivity to the parasite. A comparison of geometric mean
antibody titers showed no relationship between vaccine dose and
antibody level. The lowest dose (20 mg) of the antigen generated
the highest antibody response to the parasite after the second
immunization as well as on the last samples, while the 50 mg dose
gave the lowest antibody response to the parasite (Fig. 3). The IFA
antibody titers were consistent with the ELISA titers to the
recombinant protein in most samples. For example, a subject in
the 200 mg group who had the highest ELISA titer at 1:111,274
also had the highest IFA titer at 1:1,280 (Fig. 2).
T-cell response: In contrast to the high antibody response, the
antigen did not induce correspondingly strong T-cell responses.
Only 50% (20/40) of the participants receiving the vaccine
formulation had a positive T-cell response (SI.3). As shown in
Figure 4, after the first vaccination (day 30) no participant had a
positive T-cell response in the lowest dose group (20 mg) while
positive T-cell responses were induced 2 in the 50 mg group, 3 in
the 100 mg group and 3 in the 200 mg group, suggesting higher
dose of the vaccine required to induce the T cell response.
In vitro growth inhibition assay (GIA): Post- immunization
sera at 15% concentration did not show any significant inhibition
of parasite growth compared to the pre-immune sera (data not
shown).
Discussion
Interpretation
The primary objective of the study was to assess the safety and
reactogenicity of the PfCP-2.9 vaccine candidate formulated with
the Montanide ISA720 adjuvant in a randomized, single blinded,
placebo-controlled single center clinical trial. The results demon-
strated that the four dose levels of PfCP-2.9/ISA720 vaccine
formulation were safe and well-tolerated in Chinese adult malaria-
naı ¨ve participants. All 52 participants completed three vaccina-
tions and all follow-ups with no withdrawals or removals.
Throughout this trial, there were no severe or serious adverse
events related to the vaccinations.
High frequencies of local reactions to the vaccinations were
observed in this study, but the majority of events were graded as
mild. 6 participants developed moderate local adverse events. The
rapidly occurring local adverse events such as tenderness, pain and
swelling were observed after injections and mostly disappeared
within 1 week. The delayed reaction, injection site induration
(including suspected nodules), occurred 2 to 4 weeks following
vaccination and lasted from 4 to 13 days. These observations were
similar to that in other studies using the Montanide ISA720
adjuvant in humans where the delayed reactions developed only in
those participants receiving the antigen [23,24]. Moreover, the
frequency of the adverse reactions was higher in the participants
Table 7. Geometric mean ELISA titers and seroconversion.
Groups Seroconversion* GMT (95% CI)*** Titers
n** % Minimum Maximum
20 mg
Day 30 10 100 2660 (1540, 4593) 966 10539
Day 60 10 100 3010 (1721, 5266) 870 19362
Day 90 10 100 14352( 7926, 25989) 2188 42100
Day 180 9 90 2734(1430, 5228) 464 18493
Day 194 10 100 15097 (8647, 26358) 5434 50310
Day 240 10 100 15194 (9095, 25383) 5722 48254
50 mg
Day 30 9 90 2317 (1077, 4984) 478 8676
Day 60 10 100 2420 (1232, 4754) 500 8509
Day 90 10 100 10444(6112, 17848) 2346 32025
Day 180 10 100 2729 (1492, 4994) 743 17433
Day 194 10 100 12668(6093, 26336) 2192 69372
Day 240 10 100 9666(4707, 19849) 1375 31462
100 mg
Day 30 10 100 2740 (1713, 4384) 902 6502
Day 60 10 100 2457 (1602, 3768) 1031 9538
Day 90 10 100 5591 (3070, 10182) 2017 20964
Day 180 9 90 1551 ( 728, 3307) 254 10630
Day 194 10 100 13070(6604, 25866) 2171 41423
Day 240 10 100 9642 (4570, 20343) 2171 108568
200 mg
Day 30 8 80 1648 ( 708, 3839) 318 12864
Day 60 8 80 1227 ( 619, 2436) 331 5472
Day 90 10 100 9621 (3658, 25306) 1023 111274
Day 180 7 70 2145( 904, 5085) 365 9970
Day 194 10 100 12579 (4634, 34142) 1149 74079
Day 240 10 100 10531 (4024, 27559) 1764 74079
Note:
*:ELISA titer $1:500
**:Number of participants in individual group
***:Geometric mean titers (GMTs) are calculated by exponentiating the mean of
the log-transformed values.
doi:10.1371/journal.pone.0001952.t007
Table 8. Summary of mixed model analysis of ELISA, IFA and
the Lymphocyte Stimulation Test (LST).
Fisher tests of
fixed effects F-value P-value
ELISA IFA LST ELISA IFA LST
Overall group effect 49.83 6.84 1.90 ,0.0001 0.0002 0.126
Interaction of group
and collection time
6.19 3.39 4.26 0.0004 0.0162 0.005
Note: Models use the log-transformed titer values.
doi:10.1371/journal.pone.0001952.t008
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induration developed only in the participants who received the
highest dose of the vaccine (200 mg). These results indicate that the
generation of induration and/or nodule and its severity were
antigen- as well as dose-dependent.
None of the systemic adverse events observed in this study were
judged to be related to vaccination. There was a high rate of
hypotension and hypertension observed in the trial. However, this
was equally distributed between participants in the placebo group
and those vaccinated and did not show any relationship with
increasing vaccine dose or number of immunization. In addition,
the cut-offs for categorizing a reading of hypotension or
hypertension was more rigorous that what is normal clinical
practice. These reasons were considered to be the most likely
explanation for the high frequencies of hypotension and
hypertension observed in this study. Moreover, all cases of
hypotension and hypertension were asymptomatic and no
treatment was required. Throughout the trial, 4 participants
experienced the common cold and another 6 experienced fever,
rash, headache and diarrhea. These systemic AEs were judged to
be unrelated to the vaccination.
The results of the immunogenicity evaluation of the PfCP2.9
vaccine showed that antigen specific antibody responses were
induced in the participants receiving the test vaccine. Of 40
participants receiving various doses of the test antigen, 38 had
antigen-specific antibodies with ELISA titers of greater than 1:500
(responder) after the first vaccination. Sixty-percent of vaccinated
participants had an antibody titer of more than 1:10,000 (high
responder). Importantly, these antibodies recognized native
proteins on the cultured parasite measured by IFA, and the
ELISA titers were generally consistent with IFA titers. Our results
Figure 2. Antibody response to the cultured parasite measured by IFA in sera from participants in groups receiving 20 mg, 50 mg,
100 mg and 200 mg of the test vaccine formulation and the placebo, respectively. The IFA titers in sera collected from the days 30, 60, 80,
180, 194 and 240 were indicated by different symbols. The x-axis is the volunteer’s consecutive number: No.1,10 receiving 20 mg, No.11,20
receiving 50 mg, No.21,30 receiving 1000 mg, and No.31,40 receiving 200 mg of the vaccine while No.41,52 receiving the placebo.
doi:10.1371/journal.pone.0001952.g002
Figure 3. Kinetics of geometric mean values of the IFA titers to
the parasite for the groups receiving 20 mg(A, &), 50 mg(B,D),
100 mg(C, 6) and 200 mg(D, *) of the test vaccine formulation
and the placbo(¤). The value was shown at the time-point days 0, 30,
60, 90,180,194 and 240.
doi:10.1371/journal.pone.0001952.g003
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in animals.
Immune sera from vaccinated volunteers at this concentration
did not significantly inhibit growth of cultured parasites in an in
vitro growth inhibition assay (GIA). This was in contrast to our
previous data in rabbits and monkeys showed that 15% immune
sera almost completely inhibited parasite growth in vitro [22]. A
likely explanation could be that a much lower level of specific
antibodies are induced in humans compared to that in animals. In
a previous study of five monkeys receiving the vaccine formulation,
strong immune response were generated to the vaccine antigen
with ELISA end titers of 1/867,000 to 1/5,700,000 and IFA end
titers of 1/2,560 to 1/40,960 [22], whereas in human the ELISA
as well as IFA titers of the specific antibodies were hundreds of
times lower than that in the animals. We noted only one report on
Phase I clinical trial showing that purified IgG from volunteers
vaccinated with PfAMA1 had a certain level of parasite growth
inhibition with 4 of 22 sera tested at inhibition rate of 14, 17, 18
and 50% against the FVO isolate, respectively [23]. Further
experiments could be considered for this vaccine candidate to test
total IgG or affinity-purified antibodies from vaccinated volunteers
for their biological activities.
To identify the optimal dose of PfCP-2.9 vaccine and
immunization regimens in humans, 4 different vaccine dose
regimens were tested in the current study. A mixed model analysis
of ELISA titers indicated that the overall group effect was
significant (P,0.001). However, ANOVA/LSD analysis of ELISA
titers between the 4 dose groups showed no significant difference
in geometric mean ELISA titers (P.0.05) on day 30 (post first
immunization), day 90 (post second immunization) and day 194
(post third immunization), except one comparison between the
20 mg and 100 mg groups on day 90. Therefore, no evidence of
significant dose-response relationship was observed and vaccine
doses higher than 20 mg may not be necessary. Vaccine doses
below 20 mg could be considered to identify the optimal dose in
future clinical studies.
The antibody response in all vaccine groups was efficiently
boosted after the second immunization. However, in comparing
the ELISA titers between days 90 and 194, there was no significant
difference in geometric mean titers (P.0.05) in the 4 dose groups,
Figure 4. T-cell response to the PfCP-2.9 protein by Lymphocyte Proliferation Assay. Peripheral blood mononuclear cells were separated
from blood of participants receiving either the vaccine formulation (group A to D) or the placeb(group P) on the days 0, 30, 90 and 194 and tested for
their proliferation. The results were expressed as the stimulation index (SI), SI=mean cpm of culture with the antigen/mean cpm of culture without
the antigen.
doi:10.1371/journal.pone.0001952.g004
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significantly increase the antibody levels in all groups.
Generalizability
The study sample size was designed to be able to detect large
differences in the frequency of adverse events between the dose
groups. These results demonstrating safety and tolerability of
PfCP2.9 formulated with ISA 720 in healthy Chinese adults who
are malaria naive are however not generalizable to the main target
population of the vaccine, children at risk of malaria. Further
clinical trials will be in such target populations will eventually be
required in order to obtain generalizable data.
The vaccine promisingly demonstrates immunogenicity in all
the dose ranges tested. However, complex interactions between
the host and parasite under conditions of natural malaria
exposure, and similarly, the impact of such interactions on vaccine
induced immune responses can only be further explored in trials in
settings of natural exposure in the target population. Immunoge-
nicity in the face of pre-existing immunity and natural boosting
will have to be assessed to make more generalizable conclusions.
Overall evidence
Development of a malaria vaccine against the asexual stage is
attractive because only this stage of the parasite is known to cause
disease and even death. Antibodies against merozoites are believed
to be essential for blocking the parasite invasion of host
erythrocytes [25]. IgG prepared from individuals in malaria-
endemic regions can reduce parasitemia in the malaria-infected
patient [26]. Moreover, maternal antibodies passively transferred
to the fetus provided protection against clinical malaria [27]. P.
falciparum MSP1 and AMA-1 are the two leading asexual blood-
stage vaccine antigens [28] because the molecules may be involved
in the process of merozoite invasion of erythrocytes. The C-
terminal region of MSP1-19 and AMA-1 (III) are thought to be
targets of inhibitory antibodies [13,20]and thus were selected for
the construction of this chimeric protein. The PfCP-2.9 protein
generated by fusion of the MSP1-19 and AMA-1 (III) was
demonstrated to be highly immunogenic in various animal models
and the antibodies to this chimeric protein recognized native
parasite proteins and almost completely inhibited parasite growth
in vitro. This trial, the first chimeric protein based malaria vaccine
candidate to be tested in human trials demonstrates favorable
antibody levels to the vaccine antigen in comparison to that in
other phase I clinical trials with other malaria vaccine candidates
[23,24,29].
Consistent with observations in other clinical trials using the
Montanide ISA720 adjuvant, our vaccine formulated with this
adjuvant caused a high frequency of local adverse events.
Although difficulties in differentiating induration and nodules led
to the classification of suspected nodules as induration in this trial,
it was clearly observed that some of the events such as swelling,
induration and suspected nodules were related to the higher doses
and increasing number of injections. In addition, since the conduct
of this trial, various international efforts to improve the detection
of vaccine safety data, such as the Brighton Collaboration case
definition and guidelines for nodule, swelling and induration have
been published and in future clinical testing of this formulation
[30,31,32], these definitions will be used to guide of the detection
and diagnosis of adverse events.
In conclusion, the data from this study as well as our previous
investigations [22,33,34] support the PfCP-2.9/ISA720 as a
promising blood-stage malaria vaccine for further clinical
development. The vaccine formulation was immunogenic, and
all of the vaccinated participants seroconverted to the antigen. It
was encouraging that the vaccine induced antigen specific
antibodies, and that the antibodies recognized native proteins on
the parasite. Efforts to further improve the formulation and
optimize dose and schedule of vaccination are being continued in
a second clinical trial evaluating lower vaccine doses, and a
variation in the intervals between vaccination [35]. It is hoped that
this will lead to achieving the appropriate balance between vaccine
immunogenicity and reactogenicity in future clinical development
of this promising malaria vaccine candidate.
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